NCT03400033COMPLETEDanonymous

A Phase 3 Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study in Hemodialysis Participants With Anemia of Chronic Kidney Disease to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of Daprodustat Compared to Recombinant Human Erythropoietin, Following a Switch From Recombinant Human Erythropoietin or Its Analogs

Sponsor

Source record

GlaxoSmithKline

Phase

Source record

Phase 3

Modality

AI-normalized

small molecule

Target

AI-normalized

Anemia in Chronic Kidney Disease (CKD)

Indication / condition

AI-normalized

Anaemia

Intervention

Source record

Daprodustat tablets, Matching placebo tablets, Epoetin alfa vials, Saline vials or bags

Source & freshness

Source record

NCT ID

NCT03400033

Original source

ClinicalTrials.gov

Source last updated

Jul 12, 2021

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT03400033

Title

A Phase 3 Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study in Hemodialysis Participants With Anemia of Chronic Kidney Disease to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of Daprodustat Compared to Recombinant Human Erythropoietin, Following a Switch From Recombinant Human Erythropoietin or Its Analogs

Sponsor

GlaxoSmithKline

Status

COMPLETED

Phase

Phase 3

Condition raw

Anaemia

Condition normalized

Anaemia

Modality raw

Anaemia

Modality normalized

small molecule

Target raw

Anemia in Chronic Kidney Disease (CKD)

Target normalized

Anemia in Chronic Kidney Disease (CKD)

Interventions

Daprodustat tablets, Matching placebo tablets, Epoetin alfa vials, Saline vials or bags

Public preview

Source record

The ASCEND-TD trial evaluated daprodustat, a novel prolyl hydroxylase inhibitor, against the standard of care, epoetin alfa, in hemodialysis patients with anemia. The study aimed to demonstrate daprodustat's efficacy and safety in maintaining hemoglobin levels.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 3 Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study in Hemodialysis Participants With Anemia of Chronic Kidney Disease to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of Daprodustat Compared to Recombinant Human Erythropoietin, Following a Switch From Recombinant Human Erythropoietin or Its Analogs

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03400033

Status

COMPLETED

Phase

Phase 3

Sponsor

GlaxoSmithKline

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedJul 12, 2021

Internal syncJun 05, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03400033

Indication

Anaemia

Modality

small molecule

Target

Anemia in Chronic Kidney Disease (CKD)

Intervention

Daprodustat tablets, Matching placebo tablets, Epoetin alfa vials, Saline vials or bags

Source record